Search hospitals > Georgia > Marietta

Wellstar/Kennestone Hospital

Claim this profile
Marietta, Georgia 30060
Global Leader in Cancer
Conducts research for Coronary Artery Disease
Conducts research for Breast Cancer
Conducts research for Stroke
Conducts research for Recurrence
83 reported clinical trials
11 medical researchers
Photo of Wellstar/Kennestone Hospital in MariettaPhoto of Wellstar/Kennestone Hospital in MariettaPhoto of Wellstar/Kennestone Hospital in Marietta

Summary

Wellstar/Kennestone Hospital is a medical facility located in Marietta, Georgia. This center is recognized for care of Cancer, Coronary Artery Disease, Breast Cancer, Stroke, Recurrence and other specialties. Wellstar/Kennestone Hospital is involved with conducting 83 clinical trials across 169 conditions. There are 11 research doctors associated with this hospital, such as Hans Lee, MD, Amar Patel, MD, Rishi Gupta, MD, and Salvatore Mannino, DO.

Area of expertise

1Cancer
Global Leader
Wellstar/Kennestone Hospital has run 14 trials for Cancer. Some of their research focus areas include:
Stage III
Stage IV
Stage II
2Coronary Artery Disease
Wellstar/Kennestone Hospital has run 10 trials for Coronary Artery Disease.

Top PIs

Clinical Trials running at Wellstar/Kennestone Hospital

Stroke
Mitral Valve Regurgitation
Coronary Artery Disease
Heart Attack
Myocardial Infarction or Heart Attack
Left Ventricular Dysfunction
Myocardial Infarction
Bleeding
Aneurysm
Ischemic Stroke
Image of trial facility.

Mechanical Thrombectomy

for Stroke

This trial is testing a device called the Penumbra System with Thunderbolt, which removes blood clots from the brain. It targets patients who have had a stroke due to a large vessel blockage and are eligible for clot removal procedures. The device works like a vacuum to clear the blockage and restore blood flow. The Penumbra System has been previously reported to be effective and safe in treating acute stroke caused by large intracranial vessel occlusion.
Recruiting1 award N/A7 criteria
Image of trial facility.

rFVIIa

for Hemorrhagic Stroke

The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (mRS) and decrease ongoing bleeding as compared to standard therapy.
Recruiting1 award Phase 34 criteria
Image of trial facility.

Apixaban vs Aspirin

for Stroke Prevention in Atrial Fibrillation After Brain Bleed

Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
Recruiting1 award Phase 36 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Wellstar/Kennestone Hospital?
Wellstar/Kennestone Hospital is a medical facility located in Marietta, Georgia. This center is recognized for care of Cancer, Coronary Artery Disease, Breast Cancer, Stroke, Recurrence and other specialties. Wellstar/Kennestone Hospital is involved with conducting 83 clinical trials across 169 conditions. There are 11 research doctors associated with this hospital, such as Hans Lee, MD, Amar Patel, MD, Rishi Gupta, MD, and Salvatore Mannino, DO.